About Our Clinical Research
CMI has been conducting clinical trials since 2007. CMI has been and is part of many trials focused on lipids, diabetes, obesity, atrial fibrillation and prevention of heart attacks and strokes. The current active trials are recruiting patients who have underlying heart or vascular disease, recent heart attacks, diabetes and high cholesterol. Participation in a clinical trial has many benefits including free medication, lab tests and study related medical care.
The current trials CMI is conducting our Phase III or Phase IV trials. Phase III and Phase IV trials are conducted when the late in the stage of a drug development when several safety studies have already been conducted. These studies are very closely monitored to ensure patient safety.
Current Active Trials (recruiting patients)
Click on trial names for more information
ACCENTUATE: Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin with Ezetimibe to Evaluate LDL-C Lowering in Patients with Primary Hyperlipidemia (Eli-Lilly)
CIRT (Cardiovascular Inflammation Reduction Trial): Effect of low-dose methotrexate (LDM) in the prevention of cardiovascular events among stable coronary artery disease patients withtype 2 diabetes or metabolic syndrome (NIH sponsored study)
THEMIS: Effect of Ticagrelor on Health outcomes in diabEtes Mellitus patients Intervention Study (Astra Zeneca)
GLORIA AF: Global Registry on Longterm Oral anti-thermbotic Treatment in patients with Atrial Fibrillation
ORBIT AF II: Outcomes Registry for Better Informed Treatment of Atrial Fibrillation
Current Active Trials (not recruiting new patients)
CAMELLIA-TIMI 61: Effect of Long-term Treatment with BELVIQ (lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors
If you are interested or need more information, call us at 732-846-7000 x 7 or submit an inquiry through our Contact Us page. We look forward to hearing from you!